Opiolds have been found to modulate the immune system by regulating the function of immunocompetent cells. Several studies suggest that the interaction between immune and opioid systems is not unidirectional, but rather reciprocal, in nature. In the CNS, one cellular target of immune system activation is the astrocytes. These glial cells have been shown to produce the oploid peptide, proenkephalin, to express the it-, 6-, and K-opioid receptors, and to respond to the immune factor interleukin-1/3 (IL1/3) with an increased proenkephalin synthesis. To characterize more completely the astrocytic opioid response to immune factor stimulation, we examined the effect of IL1/3 (1 ng/ml) on the is-receptor mRNA expression in primary astrocyteenriched cultures derived from rat (postnatal day 1-2) cortex, striatum, cerebellum, hippocampus, and hypothalamus. A 24-h treatment with IL1/3 produced a 70-80% increase in the ti-receptor mRNA expression in the striatal, cerebellar, and hippocampal cultures but had no effect on this expression in the cortical and hypothalamic cultures. This observation represents one of the few demonstrated increases in levels of the it-receptor mRNA in vitro or in vivo, since the cloning of the receptor. The enhanced he-receptor mRNA expression, together with the previous observation that ILl/I stimulates proenkephalin synthesis in astrocytes, supports the ILl /3-mediated regulation of an astroglial opioid peptide and receptor in vitro, a phenomenon that may be significant in the modulation of the gliotic response to neuronal damage. Therefore, the astroglial opioid "system" may be important in the ILl /3-initiated, coordinated response to CNS infection, trauma, or injury. Key Words: Astrocytes-Interleukin-1/3-~t-Opioid receptor-Immune system activation-Immune-opioid system interactions. J. Neurochem. 66, 425-428 (1996).
Opiates, such as morphine and heroin, as well as endogenous opioid peptides, such as endorphins, enkephalins, and dynorphins, exert their biological effects via the activation of specific opioid receptors, classified as bt, 6, and K (Goldstein, 1987) . Opioids have been found to modulate the immune system by regulating the growth, proliferation, and activity of various immunocompetent cells (Sibinga and Goldstein, 1988) . However, studies suggest that the interaction between the opioid and immune systems is not unidirectional, but rather reciprocal, in nature (Blalock, 1989) . In the CNS, one cellular target of immune system activation is the astrocytes, glial cells that are believed to play a critical role in the response to CNS infection and to neuronal trauma or injury.
Astrocytes have been shown to synthesize proenkephalin (Vilijn et al., 1988; Shinoda et al., 1989) and to possess opioid binding sites (Hendrickson and Lin, 1980; Lightman et al., 1983) . Two separate investigations of the regulation of astroglial enkephalin by interleukin-1/9 (IL 1/3) have demonstrated that this immune factor enhanced the proenkephalin mRNA level in a time-, concentration-, and region-dependent fashion (Low et al., 1992; Negro et al., 1992) , suggesting that the IL 1/3-mediated elevation in proenkephalin gene expression may be important in CNS infection or injury. More recently, cultured astrocytes have also been found to express the mRNA for all three opioid receptors in a manner dependent on the receptor type and the brain region from which the culture was derived (Ruzicka et al., 1995) . However, no evidence exists regarding the regulation of astrocytic opioid receptors by immune factors. The objective of the present study was to characterize more completely the nature of the astrocytic opioid response to immune factor exposure, by examining the effects of IL 1/3 on the~.t-receptor mRNA expression in several different astrocyte-enriched cultures.
EXPERIMENTAL PROCEDURES

Cell culture
Astroglial cells were isolated and cultured as described previously (Ruzicka et al., 1995) . In brief, mixed neuronalglial cell suspensions were generated from the cortex, striaturn, cerebellum, hippocampus, and hypothalamus of 1-2-day-old rat pups. A fixed cell number (5 x l0~per plate) was seeded onto each uncoated 10-cm-diameter plastic culture dish. The growth medium (Eagle's minimal essential medium with D-valine and Earle's salts plus 10% fetal calf serum and 3.2 g of glucose/500 ml) was completely replaced with ice-cold medium the next day (day 1 in vitro). Thereafter, half the growth medium was replaced every 3 days. Cells reached confluence by day 8-10 in vitro and were maintained for a total of 11 days in culture.
On day 10 in vitro, the growth medium was replaced by medium supplemented with glucose but lacking fetal calf serum and containing ILl~3(human recombinant ILl/I, 1 ng/ml; Bachem, Torrance, CA, U.S.A.) or vehicle (10 mM acetic acid). The 1 ng/ml dose of IL 1/3 was previously shown to elicit a maximal up-regulation of astroglial proenkephalin mRNA (Negro et al., 1992) . Cells were incubated with IL 1/3 or under control conditions for 24 h and were then lysed directly on the culture dishes with Trizol reagent (GibcoBRL, Grand Island, NY, U.S.A.) to extract total RNA, as described previously (Ruzicka et al., 1995) .
Immunohistochemistry for glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) Immunohistochemical analysis was performed as detailed previously (Ruzicka et al., 1995) . In brief, cells grown on glass coverslips were fixed within their culture wells with Zamboni's fixative. Primary antibody incubations were conducted with rabbit anti-GFAP and anti-NSE, whereas secondary antibody incubations were carried out with biotinylated goat anti-rabbit IgG. After adequate washing, the cells were incubated with avidin-biotin complex (Vector Elite kit; 1:50). The staining reaction, conducted in 0.1 M sodium acetate with diaminobenzidine tetrahydrochloride (Sigma, St. Louis, MO, U.S.A.), 2.5% NiSO 4 (Sigma), and 0.01% H202, was terminated by adding excess potassium phosphate-buffered saline. Coverslips were sequentially dehydrated through graded alcohols, xylene-cleared, and then mounted onto slides for viewing under a light microscope. Under the cell culture conditions described, no neurons were detected following NSE immunohistochemistry, whereas >95% of the cells were immunohistochemically positive for GFAP, an astrocyte-specific marker (Fig. 1) . In this regard, the remaining cells presumably represented other glial cell types, namely, oligodendrocytes and microglia.
Solution hybridization/RNase protection assays
Solution hybridization/RNase protection assays for~.t-opioid receptor mRNA were carried out as reported previously (Ruzicka et al., 1995) . In brief, hybridizations were conducted with a [ 32PI UTP-labeled cRNA probe generated from a 432-bp PCR fragment designated 5A 1. This fragment was cloned into a modified EcoRV site of PT7 Blue (Novagen, Madison, WI, U.S.A.). Linearization with EcoRI and complete transcription of the linearized insert yielded a cRNA of 514 bp in length. The hybridization reaction was performed at 60°Cfor an overnight period and was then terminated by addition of RNase A (40~ig/ml atroom temperature for 1 h). Following proteinase K treatment and organic extraction, the RNA was precipitated by addition of ethanol.
The obtained cRNA:mRNA fragments were heat-denatured and fractionated on a 4% polyacrylamide denaturing (7Murea) gel in lx TBE(89 mMTris, 89 mM boric acid, and 2 mM EDTA). Following electrophoresis, the gel was dried under vacuum and then exposed to x-ray film (Kodak XAR) with two enhancer screens for a period ranging from 24 h to 7 days.
Dot-blot hybridizations
To provide an index oftotal RNA quantity in each sample, 10% of each RNA sample analyzed by RNase protection assay was concomitantly analyzed by dot-blot hybridization as previously described (Ruzicka et al., 1995) . In brief, the RNA samples were heat-denatured and then directly applied,
FIG. 1.
GFAP immunohistochemical staining of a cortical glial cell culture. After 11 days in culture, the GFAP-positive cells exhibited either a flat, polygonal morphology (A) or a stellar, process-bearing morphology (B). Such a phenotype was typical of all cultures used in the study, regardless of the brain region from which they were derived or the presence or absence of ILl/I. under vacuum, to a Nytran membrane (Schleicher and Schuell, Keene, NH, U.S.A.) contained within a hybridization manifold. The RNA was fixed to the membrane by UV cross-linking using a Stratagene UV cross-linker.
Following prehybridization of the membrane, a [32P]-UTP-labeled cRNA probe for lB 15 (cyclophilin; a ubiquitous "housekeeping" gene product) was added to a final concentration of 1 x 106 cpmlml. Following an overnight hybridization at 60°C,the membrane was washed at 70°Cin 0.1 x saline-sodium citrate and 0.1% sodium dodecyl sulfate and then exposed to x-ray film (Kodak XAR) at room temperature for 5-24 h. Previous studies using northern blot analysis of astroglial RNA revealed that the IBiS cRNA probe hybridized to a single RNA species of the expected and apparent molecular size of 1.4 kb (data not shown).
Data expression and analysis
Autoradiogram signals generated from [32PJcRNA: mRNA hybrids during the solution and dot-blot hybridizations were analyzed for the gray level intensity using computerized image analysis (NIH Image). Regarding the solution hybridization, only those signals generated from the appropriately sized protected mRNA fragments were analyzed. The gray value determined for the signal generated by each protected fragment was corrected for autoradiogram exposure time and standardized with respect to the level of lB 15 expression. Differences between control and ILl/I treatment
FIG. 2.
Effects of ILl/I (1 ng/ml) on~&-receptor mRNA expression in primary astrocyte-enriched cultures. Representative autoradiograms were generated from striatal cultures following an RNase protection assay for it-receptor mRNA (A), and a dot-blot analysis for 1 Bi 5 mRNA (B). Exposures shown are for illustrative purposes only and are not necessarily those used for quantitative analysis. C: The standardized data for all five astrocyte-enriched cultures, expressed as percentages of the control value. Data are mean ±SEM (bars) values of five to 10 observations obtained in four separate studies. C, control; ILl/I, ILl/I treatment for 24 h; Ctx, cortex; Str, striatum; Cb, cerebellum; Hippo, hippocampus; Hypo, hypothalamus.°p<0.05 compared with control.
values were compared using a paired Student's t test and were considered significant if p < 0.05. Results obtained from four separate studies have been expressed as percentages (mean ±SE) of control values.
RESULTS AND DISCUSSION
A 24-h exposure of the astrocyte-enriched cultures to IL 1/3 produced a significant elevation in the /i-receptor mRNA level in those cultures derived from the striatum, cerebellum, and hippocarnpus (Fig. 2) . The enhanced u-receptor mRNA expression in these cultures, which represented an~70-80% increase beyond control levels, was observed only after a 24-h incubation with ILl/I and not after a 4-h incubation with the cytokine (data not shown). In contrast, a 24-h treatment with ILl/I did not produce any apparent change in the u-receptor mRNA level in astrocyte-enriched cultures derived from either the cortex or the hypothalamus (Fig. 2) , suggesting a brain region-dependent action of the cytokine.
The enhanced pt-receptor mRNA expression by ILl/I represents one of the few demonstrated increases in this RNA species since the cloning of the hz-receptor (Chen et al., 1993; Thompson et al., 1993; Wang et al., 1993) . In addition, it is, to our knowledge, the first demonstration that opioid receptor mRNA can be modulated by this cytokine.
The region-dependent nature of the ILl/I effect raises the question of whether this specificity results from differential ILl/I receptor expression in these cultures. Although ILl/I receptors have been localized to astrocytes (Ban et al., 1993) and ILl/I receptors have been found to be heterogeneously distributed among brain regions (Yabuuchi et al., 1994) , their relative abundance in these brain regions may not account for the observed ILl/I action. Indeed, significant levels of the ILl/I receptor have been demonstrated in the rodent cortex (Takao et al., 1990) , a brain region generating astrocyte-enriched cultures that were unresponsive to the ILl/I treatment. In contrast, relatively low levels of the ILl/I receptor have been observed in the cerebellum (Cunningham et al., 1992) , a brain region generating astrocyte-enriched cultures that responded to the ILl/I exposure with an almost doubling in their~.i-receptor mRNA levels. It is unclear whether the ILl/I receptor distributions described in these studies represent predominantly neuronal, glial, or both types of localization, but it is interesting that the region-dependent nature of the IL 1/3-elicited elevation in /t-receptor mRNA level may not be associated with the relative abundance of the ILl/I receptor in these cultures. This issue awaits further study.
The IL 1/3-mediated elevation in /i-receptor mRNA expression apparently also is not associated with the basal~i-receptor mRNA levels in these cultures. We have previously shown that cortical astrocyte-enriched cultures contain approximately twice the level of /t-receptor mRNA as each of the striatal, cerebellar, hippocampal, and hypothalamic cultures (Ruzicka et al., 1995) . Although the latter four cultures produce comparable levels of /i-receptor mRNA, only those derived from the striatum, cerebellum, and hippocampus responded to the ILl/I with an increased ti-receptor mRNA expression. Thus, the basal level of he-receptor mRNA expression did not appear to influence the capacity of the astrocytes to respond to the cytokine.
The mechanism of the ILl/I action on the /.t-receptor mRNA expression is currently not known and is complicated by the fact that the cytokine can activate both astrocytes and microglia, is produced by both these glial cell types, and may be modulated in vivo by the presence of soluble interleukin-1 receptors and an interleukin-1 receptor antagonist (Dmarello, 1991) . The astrocyte-enriched cultures in this study may contain a small proportion of microglia. Thus, the possibility that the mechanism of ILl/I action may involve, at least in part, the activation of microglia and/or the activity of endogenously-derived ILl/I cannot be dismissed. Similarly, the presence of other endogenous factors such as soluble interleukin-1 receptor or receptor antagonist, and their potential IL 1/3-modulating effects, should also be considered.
Biochemically, cyclic AMP, prostaglandin E 2, and Ca 2h ave all been implicated as intracellular signaling molecules in the actions of ILl/I (Dinarello, 1991; Rothwell, 1991) . In addition, ILl/I has been shown to induce activity of the nuclear factor AP-1 via increases in the expression of c-jun mRNA (Muegge et al., 1989) . It is interesting that the btreceptor gene promoter has also recently been characterized, by sequence analysis, to contain a consensus sequence for the cytokine response element NF-1L6 (nuclear factor-interleukin 6) (Mm et al., 1994) . Therefore, the possibility exists that ILl/I may mediate its effects on si-receptor mRNA expression either indirectly through an intracellular signaling cascade involving immediate-early gene expression (c-fos and c-jun) or directly through its own binding to a stimulatory cytokine response element on the /i-receptor gene. Alternatively, ILl /3 may up-regulate ,.t-receptor mRNA expres-sion via an increased stability, i.e., half-life, of the RNA transcript.
The physiological significance of the IL 1/3-mediated elevation in astroglial~.t-receptormRNA expression is not clear and is confounded by the fact that the cytokine effects on the~.t-receptor protein levels are currently unknown. The effects of ILl/I on the remainder of the ft-receptor biosynthetic pathway await further study. However, it is interesting to note that both ILl/I and opioids have been implicated in the modulation of cell proliferation in the CNS. CNS infection, trauma, or injury has been shown to enhance ILl/I synthesis and secretion in immunocompetent cells, neurons, and astrocytes (Dinarello, 1991; Rothwell, 1991) . The secreted ILl/I has numerous effects, including the stimulation of astrocyte proliferation (gliosis) and activity (IL1/3 and nerve growth factor synthesis) (Dinarello, 1991; Rothwell, 1991) , components of the neuroprotective response. IL 1/3 has also been shown to enhance astroglial proenkephalin synthesis (Low et al., 1992; Negro et al., 1992) . Enkephalins, in turn, have been demonstrated to exert antimitogenic effects on both neurons and astroglial cells (Stiene-Martin and Hauser, 1991; Zagon and McLaughlin, 1991) . It is therefore intriguing to speculate that the concomitant increase in astroglial proenkephalin and~.t-receptor mRNA expression by ILl/I may result in the autoregulation of the gliotic response via the enkephalinergic activation of the ft-receptors. Such a modulation of the astroglial opioid "system" (both peptide and receptor) by ILl/I would permit this cytokine to regulate finely the intensity of its own actions on astrocytes, particularly with respect to cell proliferation. A regulation of the gliotic response would minimize possible neuropathological events resulting from excessive immune system activation or chronic inflammation. Therefore, the astroglial opioid "system" may be important in the ILi/I-initiated, coordinated response to CNS infection, trauma, or injury.
